PharmPro reported that GlaxoSmithKline has announced that its Votrient (pazopanib) drug has been issued with a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Votrient® (pazopanib) will be used in the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
As part of its assessment, the CHMP reviewed safety and efficacy data from clinical studies, including one randomised, double-blind, placebo controlled, multi-centre Phase III study.
This is good news for those who have selective subtypes of advanced Soft Tissue Sarcoma.
Are you looking for a new science job? Click here to search our jobs in science now.
Follow us on Twitter @CKScienceJobs to receive more industry news and CK jobs of the week updates